Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
about
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolAcute lymphoblastic leukaemiaNew and emerging prognostic and predictive genetic biomarkers in B-cell precursor acute lymphoblastic leukemiaPotential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome BrainNovel agents and biomarkers for acute lymphoid leukemiaGenomic profiling of B-progenitor acute lymphoblastic leukemiaRedefining ALL classification: toward detecting high-risk ALL and implementing precision medicinePrognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.Childhood acute lymphoblastic leukemia: Integrating genomics into therapyPrognostification of ALL by CytogeneticsLNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitorsUse of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemiaThe origin and evolution of mutations in acute myeloid leukemiaIntegration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray studyCharacterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia.Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.Childhood B-acute lymphoblastic leukemia: a genetic update.Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profilesBET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemiaDown syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology GroupCRLF2 and JAK2 in B-progenitor acute lymphoblastic leukemia: a novel association in oncogenesis.Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL.Next-generation cDNA screening for oncogene and resistance phenotypes.Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program.A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemiaInherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children.Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemiaBiology, risk stratification, and therapy of pediatric acute leukemias: an update.Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer.Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias.A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Regulator of myeloid differentiation and function: The secret life of Ikaros.Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.Low socioeconomic status is associated with worse survival in children with cancer: a systematic review
P2860
Q23749304-9D995AC8-847A-4557-8BFA-87F4621871C1Q24602387-78F1182A-F640-4426-B74A-AA91BADFABA7Q26749177-9F683352-6B96-46D8-A282-4E3BE9AEFF35Q26765647-A4DA15B8-19A5-4172-8BC8-5D4501857A40Q26829775-D411CA9D-7D30-4097-BA4B-F558BB59D9A4Q26829976-199A40D5-D6E3-46A7-BCB2-ACD9D085E7C7Q26864460-46D3BF0E-DA0B-47E4-9E9A-F2758EF2CC37Q27851831-67D093FF-2159-457B-8731-5C37C11378A4Q28080463-EBEDCB05-2A9D-4FFE-8F6D-2583DCC733F2Q28087446-1BFCA03D-A67A-4982-A812-ABD436967A9DQ28274115-3F51F0A1-F0FF-42EA-9A63-F64FBC92497EQ28390558-DEB51D80-8120-44B0-86E4-3D37467B4D09Q29614630-E85DAC6D-F532-428D-95D7-C8846D4E093BQ30842603-446F1585-3717-44C6-B7FA-E0F333869161Q33578333-2B746987-A075-45B0-B1CF-7B33A95121C6Q33586588-ADBD00B4-B886-4C35-9423-A53218B6A0E8Q33688248-7F4C89D5-3DA2-42A8-9B36-2E1AF6D8628DQ33711119-46D494BF-86A8-4D56-AD7E-EA76DD8DA202Q33777616-7DBAD79B-DB62-4649-8C0B-41875F81EF3BQ33938184-39642E80-C681-4441-9AAD-09E34707FDE7Q34033206-98876921-3D83-4642-9522-79FBC789B7C8Q34122298-D5C0BAC0-7348-469D-B810-EDBB3A188E8FQ34168482-77BA48A6-0026-4EDD-B94F-1EBA85E4FE66Q34172033-349A9787-6641-4B9F-A58F-3B70262709AFQ34314927-DBFE1F8D-5721-4CDE-BC0E-2CAE23AD9D10Q34325528-3F3C24EA-5E82-4215-A685-E5C028E56AA0Q34474239-8678A4D0-BA1D-4834-9496-FC69EA6DA263Q34475748-6ADD046D-ECEE-40CD-8327-E4DCF50AE1A0Q34477517-797A42D3-4AEF-4BCC-B6F5-47EE1AAEAC2EQ34482019-05AB3D9A-6307-4A6C-A6DF-690571B78223Q34707213-E9710EB0-BD29-4286-A960-A4C47BB2B700Q34755687-FB1239CD-7AB6-4F6B-ABD6-C3886AE4085BQ34764504-89214DCF-E4C5-4331-8759-D0E755267BD3Q34820332-30D683AE-80BA-4078-BE3B-34D73021C81EQ34973772-6C9DCAB5-0DDD-4942-BAFE-7F24E8660186Q35004970-A575A91E-F760-4C2E-B8F9-C321CA71BD1DQ35079398-B747BE54-D7F8-4932-84D0-2021E27EA2A7Q35103926-FBA962E7-1ADC-4D16-A955-60F6441DCB40Q35106033-BCAEB827-BC15-464C-A723-F4CADB4DE6F2Q35107431-CFC8E20B-F47A-49C9-8092-6306F0CE35CC
P2860
Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@ast
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@en
type
label
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@ast
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@en
prefLabel
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@ast
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@en
P2093
P2860
P50
P1433
P1476
Rearrangement of CRLF2 is asso ...... r acute lymphoblastic leukemia
@en
P2093
Andrew J Carroll
Bruce M Camitta
Cheryl L Willman
Fady M Mikhail
Gregory H Reaman
Huining Kang
I-Ming Chen
James R Downing
Kevin K Dobbin
Malcolm A Smith
P2860
P304
P356
10.1182/BLOOD-2009-09-245944
P407
P577
2010-02-04T00:00:00Z